Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

Celularity, Inc. announced the FDA has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).